丰原药业(000153) - 2024 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2024 reached ¥953,546,375.14, a 1.59% increase compared to ¥938,651,075.22 in the same period last year[3] - Net profit attributable to shareholders was ¥47,090,358.25, representing a 19.37% increase from ¥39,448,311.09 year-on-year[3] - Total operating revenue for Q3 2024 reached CNY 3,261,422,843.25, a slight increase from CNY 3,224,068,934.15 in Q3 2023, representing a growth of approximately 1.1%[12] - Net profit attributable to shareholders of the parent company was CNY 147,302,850.89, compared to CNY 142,464,110.40 in the same period last year, reflecting an increase of about 3.9%[13] - The total comprehensive income for Q3 2024 was CNY 144,282,495.70, compared to CNY 140,606,279.05 in Q3 2023, showing an increase of approximately 2.0%[13] - Basic and diluted earnings per share for Q3 2024 were both CNY 0.3169, up from CNY 0.3065 in the same quarter last year, reflecting a growth of about 4.5%[13] Cash Flow - Operating cash flow for the year-to-date was ¥68,460,340.27, down 48.66% from ¥133,341,879.10 in the same period last year[3] - The company's cash flow from operating activities decreased to CNY 2,682,758,366.83 from CNY 3,023,688,955.57, indicating a decline of about 11.3%[14] - Operating cash inflow for Q3 2024 was CNY 2,781,604,846.41, a decrease of 11.7% from CNY 3,148,373,200.66 in Q3 2023[15] - Cash paid for operating activities totaled CNY 2,713,144,506.14, down from CNY 3,015,031,321.56 in Q3 2023[15] - Cash inflow from investment activities was CNY 35,392,875.10, a significant increase from CNY 5,262,409.25 in the same quarter last year[15] - Net cash outflow from investing activities was CNY -181,649,402.46, compared to CNY -80,895,683.60 in the same period last year[15] - Net cash inflow from financing activities was CNY 32,337,711.28, a significant improvement from a net outflow of CNY -193,292,819.97 in Q3 2023[16] Assets and Liabilities - Total assets increased by 6.22% to ¥4,664,424,666.33 from ¥4,391,320,148.20 at the end of the previous year[4] - The total liabilities increased to CNY 2,642,217,662.71 from CNY 2,472,494,405.67, marking a rise of approximately 6.9% year-over-year[12] - The total non-current liabilities amounted to CNY 482,814,470.95, an increase from CNY 458,858,350.32, representing a growth of approximately 5.2%[12] - The total current assets at the end of the reporting period amounted to approximately CNY 2.02 billion, an increase from CNY 1.90 billion at the beginning of the period, reflecting a growth of about 5.8%[9] - Accounts receivable increased to approximately CNY 1.02 billion from CNY 791.52 million, representing a growth of about 29.1%[9] - Inventory at the end of the period was approximately CNY 579.24 million, slightly up from CNY 573.58 million, indicating a marginal increase of about 1.2%[10] - Non-current assets totaled approximately CNY 2.65 billion, up from CNY 2.49 billion, marking an increase of about 6.5%[10] - Short-term borrowings increased to approximately CNY 383.14 million from CNY 344.29 million, which is an increase of about 11.3%[10] - The company's total equity rose to CNY 2,022,207,003.62 from CNY 1,918,825,742.53, indicating an increase of about 5.4% year-over-year[12] Investment and Subsidies - The company reported a significant decrease in cash flow from investment activities, amounting to -¥181,649,402.46, a 124.55% decline year-on-year[7] - Government subsidies recognized in the current period amounted to ¥41,454,662.17, a 76.90% increase from ¥23,433,964.66 in the previous year[6] - The company reported a significant increase in long-term equity investments, remaining stable at approximately CNY 2.01 million, indicating a focus on maintaining investment levels[10] Operational Performance - The company has not reported any new product launches or major strategic changes during this reporting period, focusing instead on optimizing existing operations and financial management[9] - The operating profit for Q3 2024 was CNY 183,197,651.08, slightly down from CNY 188,918,838.94 in Q3 2023, reflecting a decrease of approximately 3.8%[12] - Research and development expenses were not reported for the current period, while the previous period recorded CNY 40,361,583.34[12]